Can minimal residual disease (MRD) measurements aid your clinical decision-making?


Learn more about using MRD in practice from leading experts

As treatments for hematological malignancies become more effective, the need for more sensitive testing arises.
Listen to experts from across the globe presenting data and discussing the latest developments in MRD measurement.

Filter by:

The relevance of MRD assessment in the clinical management of multiple myeloma patients

View the expert presentations and join in on the interactive case studies by selecting your choices to the poll questions.


Dr. Lanny Kirsch, Senior Vice President of Translational Medicine at Adaptive Biotechnologies, on the prognostic values of MRD in Multiple Myeloma (MM)

Dr. Bruno Paiva, University of Navarra, on the relevance of depth of response and sustained MRD negativity in Multiple Myeloma (MM)

Dr. Karthik Ramasamy, Consultant Hematologist at the Oxford University Hospitals NHS Foundation Trust, on managing Multiple Myeloma (MM) in practice: How can MRD inform treatment decisions?

Explore the utility of clonoSEQ®

How it Works Clinical Data

Contact Us

Make an inquiry to learn more about our products.

Request information